Hepatocellular carcinoma: Molecular interactions between hepatitis C virus and p53 in hepatocarcinogenesis

Expert Reviews in Molecular Medicine

Volumn 5, Issue 28, 2003, Pages 1-16

  Anzola, Mónica ^a   Burgos, Juan José ^b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

Author keywords

core protein; HCC; HCV; hepatitis C virus; hepatocarcinogenesis; hepatocellular carcinoma; NS3 protein; NS5A protein; p53

Indexed keywords

CORE PROTEIN; PROTEIN P53;

GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PHYSIOLOGY; REVIEW; TUMOR SUPPRESSOR GENE; VIROLOGY; VIRUS GENOME;

CARCINOMA, HEPATOCELLULAR; GENES, P53; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; VIRAL CORE PROTEINS;

EID: 84867536275     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399403006926     Document Type: Article

References (154)

1. Hussain, S.A. et al. (2001) Hepatocellular carcinoma. Ann Oncol 12, 161-172, PubMed: 11300318 (Pubitemid 32223862)
2. Brechot, C. et al. (2000) Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 10, 211-231, PubMed: 10936070 (Pubitemid 30614221)
3. el-Serag, H.B. (2001) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 5, 87-107, vi, PubMed: 11218921 (Pubitemid 32118640)
4. Dusheiko, G.M. et al. (1992) Treatment of small hepatocellular carcinomas. Lancet 340, 285-288, PubMed: 1353202
5. El-Serag, H.B. and Mason, A.C. (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340, 745-750, PubMed: 10072408 (Pubitemid 29114292)
6. Colombo, M. (1997) Treatment of hepatocellular carcinoma. J Viral Hepat 4 Suppl 1, 125-130, PubMed: 9097291
7. Akriviadis, E.A. et al. (1998) Hepatocellular carcinoma. Br J Surg 85, 1319-1331, PubMed: 9782009 (Pubitemid 28468331)
8. Zoulim, F. et al. (2003) Clinical consequences of hepatitis C virus infection. Rev Med Virol 13, 57-68, PubMed: 12516062 (Pubitemid 36125505)
9. Wogan, G.N. (1989) Dietary risk factors for primary hepatocellular carcinoma. Cancer Detect Prev 14, 209-213, PubMed: 2559796
10. Kensler, T.W. et al. (2002) Strategies for chemoprevention of liver cancer. Eur J Cancer Prev 11 Suppl 2, S58-64, PubMed: 12570336 (Pubitemid 35265864)
11. Macdonald, G.A. (2001) Pathogenesis of hepatocellular carcinoma. Clin Liver Dis 5, 69-85, PubMed: 11218920
12. Romeo, R. and Colombo, M. (2002) The natural history of hepatocellular carcinoma. Toxicology 181-182, 39-42, PubMed: 12505282 (Pubitemid 36015670)
13. Hino, O. et al. (2002) Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma. J Gastroenterol 37, 883-887, PubMed: 12483242 (Pubitemid 35423039)
14. Wisnom, C. and Siegel, M.A. (2003) Advances in the diagnosis and management of human viral hepatitis. Dent Clin North Am 47, 431-447, PubMed: 12848458 (Pubitemid 38952635)
15. Flamm, S.L. (2003) Chronic hepatitis C virus infection. Jama 289, 2413-2417, PubMed: 12746366 (Pubitemid 37430175)
16. Waris, G. (2003) Regulatory mechanisms of viral hepatitis B and C. J Biosci 28, 311-321, PubMed: 12734409 (Pubitemid 36512806)
17. Wang, X.W. et al. (2002) Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 181-182, 43-47, PubMed: 12505283 (Pubitemid 36015671)
18. Dominguez-Malagon, H. and Gaytan-Graham, S. (2001) Hepatocellular carcinoma: an update. Ultrastruct Pathol 25, 497-516, PubMed: 11783914 (Pubitemid 34008404)
19. Robinson, W.S. and Marion, P.L. (1988) Biological features of hepadna viruses. In Viral Hepatitis and Liver Disease (Zuckerman, A.J., ed.), pp. 449, Alan Liss, New York
20. Heathcote, J., Cameron, C.H. and Dane, D.S. (1974) Hepatitis-B antigen in saliva and semen. Lancet 1, 71-73, PubMed: 4129209
21. Alter, H.J., Holland, P.V. and Purcell, R.H. (1975) The emerging pattern of post-transfusion hepatitis. Am J Med Sci 270, 329-334, PubMed: 1235474
22. Szmuness, W. et al. (1975) On the role of sexual behavior in the spread of hepatitis B infection. Ann Intern Med 83, 489-495, PubMed: 1166979
23. Beasley, R.P. et al. (1977) The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 105, 94-98, PubMed: 835566 (Pubitemid 8042976)
24. Chang, M.H. et al. (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336, 1855-1859, PubMed: 9197213
25. Lin, S.M. et al. (1999) Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29, 971-975, PubMed: 10051505
26. Ikeda, K. et al. (1998) Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 82, 827-835, PubMed: 9486570 (Pubitemid 28104160)
27. Favre, D., Petit, M.A. and Trepot, C. (2003) Latent hepatitis B virus (HBV) infection and HBV DNA integration is associated with further transformation of hepatoma cells in vitro. Altex 20, 131-142, PubMed: 12947486
28. Paterlini-Brechot, P. et al. (2003) Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 22, 3911-3916, PubMed: 12813464 (Pubitemid 36819664)
29. Ferber, M.J. et al. (2003) Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 22, 3813-3820, PubMed: 12802289 (Pubitemid 36760744)
30. Schluter, V. et al. (1994) Integrated hepatitis B virus X and 3' truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene 9, 3335-3344, PubMed: 7936659
31. Caselmann, W.H. et al. (1990) A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. Proc Natl Acad Sci USA 87, 2970-2974, PubMed: 2158099
32. Ryu, W.S. (2003) Molecular aspects of hepatitis B viral infection and the viral carcinogenesis. J Biochem Mol Biol 36, 138-143, PubMed: 12542984
33. Koike, K. (2002) Hepatocarcinogenesis in hepatitis viral infection: lessons from transgenic mouse studies. J Gastroenterol 37 Suppl 13, 55-64, PubMed: 12109667 (Pubitemid 34846309)
34. Koike, K. et al. (2002) Molecular mechanism of viral hepatocarcinogenesis. Oncology 62 Suppl 1, 29-37, PubMed: 11868782 (Pubitemid 34702017)
35. Zhang, Y. et al. (2002) Overexpression of cyclin A in hepatocellular carcinoma and its relationship with HBx gene integration. Zhonghua Zhong Liu Za Zhi 24, 353-355, PubMed: 12408762
36. Caselmann, W.H. (1995) Transactivation of cellular gene expression by hepatitis B viral proteins: a possible molecular mechanism of hepatocarcinogenesis. J Hepatol 22, 34-37, PubMed: 7602073
37. Crowson, A.N. et al. (2003) The dermatopathologic manifestations of hepatitis C infection: a clinical, histological, and molecular assessment of 35 cases. Hum Pathol 34, 573-579, PubMed: 12827611 (Pubitemid 36750369)
38. Laporte, J. et al. (2003) Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. Blood 101, 52-57, PubMed: 12393733 (Pubitemid 36025886)
39. Resti, M. et al. (2002) Injection drug use facilitates hepatitis C virus infection of peripheral blood mononuclear cells. Clin Infect Dis 35, 236-239, PubMed: 12115087 (Pubitemid 34800269)
40. Caussin-Schwemling, C., Schmitt, C. and Stoll-Keller, F. (2001) Study of the infection of human blood derived monocyte/macrophages with hepatitis C virus in vitro. J Med Virol 65, 14-22, PubMed: 11505438
41. El-Serag, H.B. (2002) Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36, S74-83, PubMed: 12407579 (Pubitemid 35253466)
42. Seeff, L.B. (2002) Natural history of chronic hepatitis C. Hepatology 36, S35-46, PubMed: 12407575 (Pubitemid 35253462)
43. Alberti, A. and Benvegnu, L. (2003) Management of hepatitis C. J Hepatol 38 Suppl 1, S104-118, PubMed: 12591189
44. Chander, G. et al. (2002) Treatment of chronic hepatitis C: a systematic review. Hepatology 36, S135-144, PubMed: 12407587 (Pubitemid 35253474)
45. Pockros, P.J. et al. (2003) The safety and tolerability of daily infergen plus ribavirin in the treatment of naiive chronic hepatitis C patients. J Viral Hepat 10, 55-60, PubMed: 12558913 (Pubitemid 36237813)
46. Houghton, M. et al. (1991) Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 14, 381-388, PubMed: 1650328
47. Takamizawa, A. et al. (1991) Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 65, 1105-1113, PubMed: 1847440
48. Choo, Q.L. et al. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362, PubMed: 2523562
49. Kato, N. et al. (1990) Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 87, 9524-9528, PubMed: 2175903 (Pubitemid 120016475)
50. Han, J.H. et al. (1991) Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end. Proc Natl Acad Sci USA 88, 1711-1715, PubMed: 1705704 (Pubitemid 21916295)
51. Sobolev, B.N. et al. (2002) [Analysis of hepatitis C virus proteins based on amino acid sequence data and literature data]. Biofizika 47, 204-210, PubMed: 11969155
52. Roccasecca, R. et al. (2003) Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol 77, 1856-1867, PubMed: 12525620 (Pubitemid 36109998)
53. Vizmanos, J.L. et al. (1998) Degree and distribution of variability in the 5' untranslated, E1, E2/NS1 and NS5 regions of the hepatitis C virus (HCV). J Viral Hepat 5, 227-240, PubMed: 9751009
54. Shi, S.T. and Lai, M.M. (2001) Hepatitis C viral RNA: challenges and promises. Cell Mol Life Sci 58, 1276-1295, PubMed: 11577984 (Pubitemid 32844098)
55. Kato, N. (2000) Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation. Microb Comp Genomics 5, 129-151, PubMed: 11252351 (Pubitemid 32183233)
56. De Francesco, R. et al. (2000) Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: implications for development of antiviral agents and vaccines. Semin Liver Dis 20, 69-83, PubMed: 10895433 (Pubitemid 30421410)
57. Simmonds, P. (1995) Variability of hepatitis C virus. Hepatology 21, 570-583, PubMed: 7531173
58. Okamoto, H. et al. (1992) Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 190, 894-899, PubMed: 1325713
59. Tran, H.T. et al. (2003) Prevalence of hepatitis virus types B through E and genotypic distribution of HBV and HCV in Ho Chi Minh City, Vietnam. Hepatol Res 26, 275-280, PubMed: 12963426 (Pubitemid 37184515)
60. Zheng, X. et al. (2003) Direct comparison of hepatitis C virus genotypes tested by INNO-LiPA HCV II and TRUGENE HCV genotyping methods. J Clin Virol 28, 214-216, PubMed: 12957191 (Pubitemid 37040872)
61. Craxi, A. and Licata, A. (2003) Clinical trial results of peginterferons in combination with ribavirin. Semin Liver Dis 23 Suppl 1, 35-46, PubMed: 12934167 (Pubitemid 37052443)
62. Okamoto, H. et al. (1992) Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 73 (Pt 3), 673-679, PubMed: 1312125
63. Tsukiyama-Kohara, K. et al. (1991) A second group of hepatitis C viruses. Virus Genes 5, 243-254, PubMed: 1663293
64. Fan, X. et al. (1999) Comparison of genetic heterogeneity of hepatitis C viral RNA in liver tissue and serum. Am J Gastroenterol 94, 1347-1354, PubMed: 10235217 (Pubitemid 29214652)
65. Kobayashi, M. et al. (1997) Antibody response to E2/NS1 hepatitis C virus protein in patients with acute hepatitis C. J Gastroenterol Hepatol 12, 73-76, PubMed: 9076628 (Pubitemid 27100170)
66. Vogelstein, B. et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319, 525-532, PubMed: 2841597
67. Feo, F. et al. (2000) Genetic alterations in liver carcinogenesis: implications for new preventive and therapeutic strategies. Crit Rev Oncog 11, 19-62, PubMed: 10795626 (Pubitemid 30220598)
68. Buendia, M.A. (2000) Genetics of hepatocellular carcinoma. Semin Cancer Biol 10, 185-200, PubMed: 10936068
69. Sheu, J.C. (1997) Molecular mechanism of hepatocarcinogenesis. J Gastroenterol Hepatol 12, S309-313, PubMed: 9407351
70. Tsuda, H. et al. (1989) Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res 80, 196-199, PubMed: 2542205 (Pubitemid 20027206)
71. Oda, T. et al. (1992) p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 52, 6358-6364, PubMed: 1330291
72. Vogelstein, B. and Kinzler, K.W. (1992) p53 function and dysfunction. Cell 70, 523-526, PubMed: 1505019
73. Hollstein, M. et al. (1991) p53 mutations in human cancers. Science 253, 49-53, PubMed: 1905840
74. Hsu, I.C. et al. (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350, 427-428, PubMed: 1849234 (Pubitemid 21912245)
75. Murakami, Y. et al. (1991) Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 51, 5520-5525, PubMed: 1655254
76. Theobald, M. and Offringa, R. (2003) Anti-p53-directed immunotherapy of malignant disease. Exp. Rev. Mol. Med. Vol. 5, 28 March, DOI: 10.1017/S1462399403006173
77. Kern, S.E. et al. (1991) Identification of p53 as a sequence-specific DNA-binding protein. Science 252, 1708-1711, PubMed: 2047879 (Pubitemid 21917093)
78. Ko, L.J. and Prives, C. (1996) p53: puzzle and paradigm. Genes Dev 10, 1054-1072, PubMed: 8654922 (Pubitemid 26152848)
79. Amundson, S.A., Myers, T.G. and Fornace, A.J., Jr. (1998) Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 17, 3287-3299, PubMed: 9916991 (Pubitemid 29043981)
80. el-Deiry, W.S. (1998) Regulation of p53 downstream genes. Semin Cancer Biol 8, 345-357, PubMed: 10101800 (Pubitemid 29131356)
81. Kastan, M.B. et al. (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597, PubMed: 1423616
82. el-Deiry, W.S. et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825, PubMed: 8242752 (Pubitemid 23346378)
83. Juven-Gershon, T. and Oren, M. (1999) Mdm2: the ups and downs. Mol Med 5, 71-83, PubMed: 10203572 (Pubitemid 29230686)
84. Hermeking, H. et al. (1997) 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1, 3-11, PubMed: 9659898 (Pubitemid 127376388)
85. Polyak, K. et al. (1997) A model for p53-induced apoptosis. Nature 389, 300-305, PubMed: 9305847 (Pubitemid 27406646)
86. Levine, A.J., Momand, J. and Finlay, C.A. (1991) The p53 tumour suppressor gene. Nature 351, 453-456, PubMed: 2046748 (Pubitemid 21896613)
87. Oren, M. (1992) p53: the ultimate tumor suppressor gene? Faseb J 6, 3169-3176, PubMed: 1397838
88. Montenarh, M. (1992) Biochemical properties of the growth suppressor/oncoprotein p53. Oncogene 7, 1673-1680, PubMed: 1501881
89. Dutta, A. et al. (1993) Inhibition of DNA replication factor RPA by p53. Nature 365, 79-82, PubMed: 8361542 (Pubitemid 23305574)
90. Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell 88, 323-331, PubMed: 9039259 (Pubitemid 27131374)
91. Cross, S.M. et al. (1995) A p53-dependent mouse spindle checkpoint. Science 267, 1353-1356, PubMed: 7871434
92. Harris, C.C. and Hollstein, M. (1993) Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329, 1318-1327, PubMed: 8413413 (Pubitemid 23317333)
93. Greenblatt, M.S. et al. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54, 4855-4878, PubMed: 8069852 (Pubitemid 24289415)
94. Oren, M. (1994) Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol 5, 221-227, PubMed: 7948950 (Pubitemid 124006732)
95. Ullrich, S.J. et al. (1992) The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem 267, 15259-15262, PubMed: 1639769
96. Ljungman, M. (2000) Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 2, 208-225, PubMed: 10935507 (Pubitemid 30346077)
97. Appella, E. and Anderson, C.W. (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268, 2764-2772, PubMed: 11358490 (Pubitemid 32862957)
98. Oyesiku, N.M. et al. (1997) Pituitary adenomas: screening for G alpha q mutations. J Clin Endocrinol Metab 82, 4184-4188, PubMed: 9398737 (Pubitemid 27525537)
99. Shaulsky, G., Ben-Ze'ev, A. and Rotter, V. (1990) Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene 5, 1707-1711, PubMed: 2267137 (Pubitemid 120034693)
100. Isaacs, J.S. et al. (1998) Differential subcellular p53 localization and function in N-and S-type neuroblastoma cell lines. Cell Growth Differ 9, 545-555, PubMed: 9690622 (Pubitemid 28345911)
101. Lilling, G. et al. (2002) Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells. Cancer Invest 20, 509-517, PubMed: 12094546 (Pubitemid 34686347)
102. Bosari, S. et al. (1995) bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol 26, 534-540, PubMed: 7750937
103. Lu, W. et al. (2000) Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene 19, 232-240, PubMed: 10645001 (Pubitemid 30077219)
104. Takada, S. et al. (1997) Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene 15, 1895-1901, PubMed: 9365235 (Pubitemid 27480677)
105. Truant, R. et al. (1995) Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J Virol 69, 1851-1859, PubMed: 7853526
106. Zhang, Y., Xiong, Y. and Yarbrough, W.G. (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734, PubMed: 9529249 (Pubitemid 28155312)
107. Weber, J.D. et al. (1999) Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1, 20-26, PubMed: 10559859 (Pubitemid 129495005)
108. Tao, W. and Levine, A.J. (1999) P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 96, 6937-6941, PubMed: 10359817 (Pubitemid 29274988)
109. Thomas, M., Pim, D. and Banks, L. (1999) The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18, 7690-7700, PubMed: 10618709 (Pubitemid 30052696)
110. Ahn, J.Y. et al. (2001) Transcriptional repression of p21(waf1) promoter by hepatitis B virus X protein via a p53-independent pathway. Gene 275, 163-168, PubMed: 11574165 (Pubitemid 32907339)
111. Ahn, J.Y. et al. (2002) Dual effects of hepatitis B virus X protein on the regulation of cell-cycle control depending on the status of cellular p53. J Gen Virol 83, 2765-2772, PubMed: 12388812 (Pubitemid 35276976)
112. Querido, E. et al. (1997) Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J Virol 71, 3788-3798, PubMed: 9094654 (Pubitemid 27172392)
113. Fabbro, M. and Henderson, B.R. (2003) Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 282, 59-69, PubMed: 12531692 (Pubitemid 36259901)
114. Inoue, T. et al. (2002) Nuclear import and export signals in control of the p53-related protein p73. J Biol Chem 277, 15053-15060, PubMed: 11847229 (Pubitemid 34952582)
115. O'Keefe, K., Li, H. and Zhang, Y. (2003) Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol Cell Biol 23, 6396-6405, PubMed: 12944468 (Pubitemid 37075753)
116. Chene, P. (2001) The role of tetramerization in p53 function. Oncogene 20, 2611-2617, PubMed: 11420672 (Pubitemid 32525291)
117. Atz, J., Wagner, P. and Roemer, K. (2000) Function, oligomerization, and conformation of tumor-associated p53 proteins with mutated C-terminus. J Cell Biochem 76, 572-584, PubMed: 10653977 (Pubitemid 30083140)
118. Liu, M.C. and Gelmann, E.P. (2002) P53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol 29, 246-257, PubMed: 12063677 (Pubitemid 34620441)
119. Nishida, N. et al. (1993) Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res 53, 368-372, PubMed: 8093350 (Pubitemid 23031851)
120. Shen, H.M. and Ong, C.N. (1996) Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res 366, 23-44, PubMed: 8921985
121. Matlashewski, G.J. et al. (1987) Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7, 961-963, PubMed: 3547088 (Pubitemid 17004567)
122. Anzola, M. et al. (2003) Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett 193, 199-205, PubMed: 12706878 (Pubitemid 36428903)
123. Okada, F. et al. (2001) A p53 polymorphism associated with increased risk of hepatitis C virus infection. Cancer Lett 172, 137-142, PubMed: 11566488 (Pubitemid 32889708)
124. Florese, R.H. et al. (2002) Inhibition of protein synthesis by the nonstructural proteins NS4A and NS4B of hepatitis C virus. Virus Res 90, 119-131, PubMed: 12457968 (Pubitemid 35375829)
125. Qadri, I., Iwahashi, M. and Simon, F. (2002) Hepatitis C virus NS5A protein binds TBP and p53, inhibiting their DNA binding and p53 interactions with TBP and ERCC3. Biochim Biophys Acta 1592, 193-204, PubMed: 12379483
126. Lee, M.N. et al. (2002) Hepatitis C virus core protein represses the p21 promoter through inhibition of a TGF-beta pathway. J Gen Virol 83, 2145-2151, PubMed: 12185267 (Pubitemid 34993719)
127. Lan, K.H. et al. (2002) HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 21, 4801-4811, PubMed: 12101418
128. Kwun, H.J. and Jang, K.L. (2003) Dual effects of hepatitis C virus Core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene. J Viral Hepat 10, 249-255, PubMed: 12823590 (Pubitemid 36801910)
129. Yamanaka, T., Kodama, T. and Doi, T. (2002) Subcellular localization of HCV core protein regulates its ability for p53 activation and p21 suppression. Biochem Biophys Res Commun 294, 528-534, PubMed: 12056798 (Pubitemid 34694040)
130. Yamanaka, T., Uchida, M. and Doi, T. (2002) Innate form of HCV core protein plays an important role in the localization and the function of HCV core protein. Biochem Biophys Res Commun 294, 521-527, PubMed: 12056797 (Pubitemid 34694039)
131. Ray, R.B., Meyer, K. and Ray, R. (1996) Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 226, 176-182, PubMed: 8955036 (Pubitemid 27025796)
132. Ray, R.B. et al. (1997) Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 272, 10983-10986, PubMed: 9110985 (Pubitemid 27184081)
133. Ray, R.B. et al. (1998) Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. Gene 208, 331-336, PubMed: 9524287 (Pubitemid 28120945)
134. Oka, K. et al. (2003) Hepatitis C virus core protein selectively inhibits synthesis and accumulation of p21/Waf1 and certain nuclear proteins. Microbiol Immunol 47, 429-438, PubMed: 12906103 (Pubitemid 36759448)
135. Alisi, A. et al. (2003) Physical and functional interaction between HCV core protein and the different p73 isoforms. Oncogene 22, 2573-2580, PubMed: 12730672 (Pubitemid 36605605)
136. Varaklioti, A. et al. (2002) Alternate translation occurs within the core coding region of the hepatitis C viral genome. J Biol Chem 277, 17713-17721, PubMed: 11884417 (Pubitemid 34967576)
137. Harper, J.W. et al. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816, PubMed: 8242751 (Pubitemid 23346377)
138. Coqueret, O. (2003) New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13, 65-70, PubMed: 12559756 (Pubitemid 36135887)
139. Zakut, R. and Givol, D. (1995) The tumor suppression function of p21Waf is contained in its N-terminal half ('half-WAF'). Oncogene 11, 393-395, PubMed: 7624153
140. Benard, J., Douc-Rasy, S. and Ahomadegbe, J.C. (2003) TP53 family members and human cancers. Hum Mutat 21, 182-191, PubMed: 12619104 (Pubitemid 36292961)
141. Ishido, S. and Hotta, H. (1998) Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. FEBS Lett 438, 258-262, PubMed: 9827557 (Pubitemid 28529285)
142. Muramatsu, S. et al. (1997) Nuclear localization of the NS3 protein of hepatitis C virus and factors affecting the localization. J Virol 71, 4954-4961, PubMed: 9188558 (Pubitemid 27258163)
143. Ishido, S. et al. (1997) Wild-type, but not mutant-type, p53 enhances nuclear accumulation of the NS3 protein of hepatitis C virus. Biochem Biophys Res Commun 230, 431-436, PubMed: 9016797 (Pubitemid 27212015)
144. Feng, D., Zheng, H. and Yan, Y. (1998) [The effect of HCV NS3 protein on expression of p53 gene protein in hepatocarcinogenesis]. Zhonghua Yi Xue Za Zhi 78, 278-280, PubMed: 10923485
145. Kwun, H.J. et al. (2001) p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J Gen Virol 82, 2235-2241, PubMed: 11514734 (Pubitemid 32827604)
146. Khabar, K.S. and Polyak, S.J. (2002) Hepatitis C virus-host interactions: the NS5A protein and the interferon/chemokine systems. J Interferon Cytokine Res 22, 1005-1012, PubMed: 12433279 (Pubitemid 35379011)
147. Reyes, G.R. (2002) The nonstructural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. J Biomed Sci 9, 187-197, PubMed: 12065893 (Pubitemid 34639027)
148. Giannini, C. and Brechot, C. (2003) Hepatitis C virus biology. Cell Death Differ 10 Suppl 1, S27-38, PubMed: 12655344 (Pubitemid 36519094)
149. Keskinen, P., Melen, K. and Julkunen, I. (2002) Expression of HCV structural proteins impairs IFN-mediated antiviral response. Virology 299, 164-171, PubMed: 12202219 (Pubitemid 35356593)
150. Ghosh, A.K. et al. (1999) Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol 80 (Pt 5), 1179-1183, PubMed: 10355764 (Pubitemid 29213805)
151. Arima, N. et al. (2001) Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. J Biol Chem 276, 12675-12684, PubMed: 11278402
152. Majumder, M. et al. (2001) Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 75, 1401-1407, PubMed: 11152513
153. Otsuka, M. et al. (2000) Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J Biol Chem 275, 34122-34130, PubMed: 10924497
154. Pawlotsky, J.M. and Germanidis, G. (1999) The non-structural 5A protein of hepatitis C virus. J Viral Hepat 6, 343-356, PubMed: 10607250 (Pubitemid 29470164)